Evidence map›Paper›PMID 40725793›Full record

ReviewJournal of clinical medicine2025

A Simple Ratio in a Complex Disease: Exploring the Neutrophil-to-Lymphocyte Ratio in Idiopathic Pulmonary Fibrosis.

Giorgio Monteleone, Luca Passantino, Jacopo Simonetti, Bruno Iovene, Francesco Varone, Paolo Cameli, Giacomo Sgalla, Luca Richeldi

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Immunosenescence in Idiopathic Pulmonary Fibrosis.Journal of inflammation research · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giorgio MonteleoneDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy.
Luca PassantinoDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0009-0004-0856-9004
Jacopo SimonettiDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0000-0001-9205-752X
Bruno IoveneFondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Francesco VaroneFondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0003-2443-8069
Paolo CameliRespiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy.ORCID 0000-0001-8639-2882
Giacomo SgallaDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy.ORCID 0000-0003-3130-9388
Luca RicheldiDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neutrophil-to-lymphocyte ratio (NLR) is a simple, inexpensive and easily accessible inflammatory biomarker that reflects the balance between innate and adaptive immunity. In recent years, NLR has emerged as a potential prognostic and disease severity marker for different diseases, including idiopathic pulmonary fibrosis (IPF), a progressive and fatal interstitial lung disease with a highly variable course and poor prognosis. Several studies have highlighted that NLR can be associated with several clinical outcomes such as lung function decline, increased risk of hospitalization, acute exacerbation of IPF, and mortality over time. It might also correlate with overall survival in the course of antifibrotic therapy and validated prognostic score as a gender-age-physiology score. Despite these findings, the clinical use of NLR remains limited due to its non-specific nature, the lack of standardized cut-off values, and high variability related to demographic factors, comorbidities and medications. Hence, NLR may display the underlying immune dysregulation in IPF and could be exploited as a non-invasive tool for risk stratification and disease monitoring. Further studies are needed to confirm and validate its use in IPF and to establish reliable cut-off values in clinical applications.

Indexed as

biomarkeridiopathic pulmonary fibrosisinflammationneutrophil-to-lymphocyte ratio

Identifiers

PMID40725793
PMCPMC12294870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.